KR20080049504A - Functional oil including fucosterol useful for the improvement of blood circulation and control of hyperlipidemia - Google Patents

Abstract

A functional oil comprising fucosterol is provided to show strong cholesterol metabolism improving functionality such as inhibition of cholesterol biosynthesis and lowering cholesterol in blood and improve blood circulation, thereby being used for preventing and treating hyperlipidemia. A functional oil comprises: a fucosterol solubilized fucosterol oil; and oils and fats, wherein the fucosterol solubilized fucosterol oil is obtained by adding 100-500ml of a vegetable oil and 10-50mg of tocophenol to 1g of fucosterol powder and agitating the mixture. A method for isolating fucosterol from sea algae comprises the steps of: (a) after adding a sea algae raw material remained after extraction of a water-soluble extract ingredient from the sea algae to an edible alcohol, grinding it to obtain a sea algae alcohol treating solution; (b) after adding an edible alcohol to the alcohol treated solution of the sea algae, subjecting to the ultrasonic wave treatment at high temperature to extract non polar materials from the sea algae raw material; (c) filtering the non polar material extracted alcohol treated sea algae to obtain a filtrate, removing the alcohol therefrom to obtain a non-polar extract of the sea algae raw material; (d) after adding KOH-ethanol solution, which is able to be added as a food additive, to the non-polar extract and mixing them, hydrolyzing it at high temperature to remove saponifying materials therefrom and cooling it to obtain a hydrolysate of the sea algae; and (e) after shaking-extracting the sea algae hydrolysate by adding a solvent having the different polarity from that of the non-polar material in a liquid-liquid separating device, allowing it to stand still to liquid-liquid separate a polar fraction and a non-polar fraction and removing co-existing moisture therefrom, filtering the non-polar fraction to remove impurities therefrom, removing other solvent with the different polarity from that of the non-polar material and then drying it to obtain fucosterol. Further, the fucosterol solubilized fucosterol oil, a seed oil of evening primrose and an olive oil is mixed at a volume rate of 1~5 : 50~95 : 5~45.

Description

Functional oil including fucosterol useful for the improvement of blood circulation and control of hyperlipidemia

1 is a blood lipid composition of a test animal (hamster) orally administered with a high-fat diet fucosterol-containing functional oil devised by the present invention,

Figure 1a is a graph showing the composition of triglyceride (triglyceride) in the blood lipid component of the experimental animal,

Figure 1b is a graph showing the composition of total cholesterol (total choleserol) of blood lipid components of the experimental animal,

Figure 1c is a graph showing the composition of HDL-cholesterol (HDL-choleserol) in the blood lipid components of the experimental animal,

Figure 1d is a graph showing the composition of LDH-cholesterol (LDH-choleserol) in blood lipid components of experimental animals.

Figure 2 is a graph showing the blood flow characteristics of hamsters (Hamster) orally administered with a high fat diet of the fucosterol-containing functional oil devised by the present invention.

The present invention relates to a functional oil containing fucosterol, which has an effect of improving blood flow and improving blood lipid components, and more specifically, improves blood flow, including fucosterol oil and fats and oils in which fucosterol is solubilized. The present invention relates to a functional oil containing fucosterol having an effect on improving blood lipid components and improving blood flow and improving blood lipid components, which can be used to improve blood flow and prevent and treat hyperlipidemia.

Hyperlipidemia (hyperlipidemia, 高脂 血症) refers to a condition in which the lipid content in the blood is increased to an abnormal level and generally means an increase in cholesterol or triglycerides in the blood.

Hyperlipidemia, which causes blood cholesterol levels to rise above a certain level, more specifically hypercholesterolemia or hypertriglyceridemia, leads to blood flow deterioration, increased blood pressure, and peripheral disease due to the development of blood viscosity and atherosclerosis. Preventing and treating blood circulation in the blood vessels, as well as increasing the likelihood of developing ischemic heart disease, prevents and treats them as a top priority for the health of modern people.

The treatment of hyperlipidemia is carried out individually or in combination with diet, exercise and drug therapy, taking into account the state of hyperlipidemia, the patient's dietary habits or family history of hyperlipidemia, the presence of arteriosclerosis, age, and other comorbidities (risk factors). The main goal is to prevent atherosclerotic disease, coronary artery disease, and ischemic heart disease by treating cholesterol in the blood at least 240 mg / dl or less and 200 mg / dl as much as possible.

Considering that more than 80% of the cholesterol in the body is synthesized in the liver and the absorption from food is relatively large and the effect of the number of LDL-Cholesterol recepters is inevitably large, the function as an anti-hyperlipidemic food material is Biosynthesis inhibitory activity and cholesterol absorption inhibitory effect may be important determinants.

HMG-Co A reductase, an enzyme that converts HMG-CoA (3-hydroxy-methyl glutaryl coenzyme A) into mevalonate during cholesterol biosynthesis, is a rate-limiting enzyme of cholesterol synthesis rate and HMG-CoA reductase activity in liver Decreased levels of hepatic LDL-recepter increase the activity of the blood cholesterol levels known to reduce the action is widely used in the treatment of related diseases. Serum cholesterol lowering agents include bile acid-binding resins, cholesterol synthesis inhibitors, nicotinic acid derivatives, and probucol. Among these, cholesterol inhibitors such as simvastatin or lovastatin inhibit HMG-CoA reductase. At the same time, it is known to have an effect of lowering blood cholesterol by inducing LDL receptor mRNA expression. However, these cholesterol synthesis inhibitors are effective in the short-term, but side effects due to long-term use has been reported, it can be said that the development of natural substances with excellent cholesterol-lowering properties suitable for long-term use from natural products.

Until now, there have been various researches on functional food materials for reducing blood cholesterol levels and improving blood circulation.By biosynthesis of functional extracts, dietary fiber such as dietary fiber and traditional Chinese medicine, refined fish oil containing omega-3 series EPA and DHA, and prostaglandin Research has focused on the extracts of the essential fatty acid gammalinolenic acid (γ-linolenic acid, GLA), ginkgo biloba and red ginseng used as precursors, and the interest in anti-hyperlipidemic activity and blood flow promoters derived from algae is gradually increasing. It is rising.

In this regard, Fucosterol derived from seaweed is a relatively low molecular substance and is a type of phytosterol that is easily absorbed and has lowered cholesterol. However, the expectation for effective utilization is gradually increasing due to the limitation of related basic and applied research. Development of industrially useful related technologies has not been actively made yet.

Fucosterol is one of the phytosterols, but it is mainly present in seaweed and differs from land plant-derived phytosterol in that it contains fucose in its molecular structure.

Vegetable sterols have not received much nutritional attention so far, but since the 1980s derivatives such as fatty acid esters of vegetable sterols have higher affinity for animal intestinal mucosa than cholesterol in the presence of bile acids. It has been shown to be effective in inhibiting the absorption of cholesterol and decrease in total cholesterol and LDL-cholesterol in the blood, and has been in the spotlight as a functional material for the prevention and treatment of cholesterol-related adult diseases. Cholesterol-reducing effects of these plant sterols vary depending on the type and molecular structure of sterols. However, it is reported that fatty acid esters of sterols have excellent efficacy. .

Vegetable sterols contain 0.5-5% of vegetable fats and oils, but industrially, they are extracted and purified from refined by-products or pulp wastes of soybean oil.

Because fucosterol contains fucose in its molecular structure, it may have a different effect on the action from land plant-derived plant sterols, and has a low recovery and extraction rate. However, it is not only excellent in biosynthesis inhibitory activity of cholesterol at low concentrations but also improved blood flow It is known to exhibit various physiological activities such as antidiabetic and anticancer effects.

Although basic research has been conducted on the extraction and separation of fucosterol from seaweeds, most of them remain at the level of academic research for content analysis and efficacy evaluation of raw algae. It is not established. Conventional fucosterol separation mainly uses brown algae as a raw material and maximizes the extraction of fat-soluble components at room temperature using nonpolar solvents such as chloroform and methanol, followed by alkali hydrolysis and extraction of fucosterol by ethyl ether. And the extraction process of crude fucosterol obtained through the general process such as separation of the fucosterol fraction by ether-water mixed solvent, and the extraction yield is low. There was a difficult problem.

Most conventional techniques for the preparation of physiological functional compositions having cholesterol metabolism improving effects using seaweed active ingredients are mostly functional polysaccharides or dietary components, and there are few cases of technology development regarding effective utilization of fat-soluble functional components. It was a situation.

The present invention relates to a functional oil containing fucosterol containing solubilized fucosterol and a fat or oil, preferably purified fish oil containing fucosterol solubilized and EPA and DHA. It is intended to provide functional oils containing fucosterol for improving blood flow and improving hyperlipidemia, including vegetable oils with high γ-linolenic acid content.

Another object of the present invention is to provide a method for separating fucosterol used in the functional oil containing the fucosterol from seaweeds.

The functional oil containing the fucosterol of the present invention has the effect of improving the fluidity of the blood and improving the hyperlipidemia, so that it can be used for improving blood flow and preventing and treating hyperlipidemia.

The present invention for achieving the above-mentioned object represents a fucosterol-oil-functional functional oil containing a fucosterol oil and fats and oils solubilized.

The fucosterol oil solubilized with the fucosterol can be obtained by stirring the fucosterol with the vegetable fat and oil to obtain the fucosterol oil solubilized. At this time, in order to improve the functionality of the fucosterol oil solubilized fucosterol, the additives may be additionally added when the plant is maintained and stirred. As an example of the above additives, an antioxidant of tocopherol or TBH may be used.

As an example of the fucosterol oil in which the fucosterol of the present invention is solubilized, it can be obtained by adding and stirring 100 to 500 ml of vegetable oil and 10 to 50 mg of tocophenol to 1 g of fucosterol powder. At the time of fucosterol, vegetable oil and tocophenol, fucosterol, vegetable oil and tocophenol are added and heated and stirred at 40 to 80 ° C for 5 to 30 minutes, and then cooled to room temperature to make fucosterol solubilized. You can get terrol oil.

The vegetable oils and fats may be used as vegetable oils and fats.

The vegetable oil may use any one or more selected from olive oil, soybean oil, sesame oil, perilla oil, rapeseed oil, corn oil, peanut oil, red pepper seed oil, rice bran oil.

The fucosterol oil solubilized in the above can be mixed with fats and oils to obtain a functional oil containing the fucosterol.

The fat or oil may be any one or more selected from refined fish oil and edible oils and fats.

As an example of the refined fish oil, refined fish oil containing 15 to 25% of EPA and DHA may be used.

The edible oil and fat can be used as a liquid edible oil, solid edible oil.

The solid edible oil in the edible oil and fat should be dissolved in the liquid phase for ease of mixing, preferably using a liquid edible oil.

One example of the edible oil and fat may be any one or more selected from olive oil, moonflower seed oil, soybean oil, sesame oil, perilla oil, rapeseed oil, corn oil, peanut oil, red pepper seed oil, rice bran oil.

As an example of the mixing of the fucosterol-solubilized fucosterol oil and fats and oils, the fucosterol-soluble fucosterol oil, refined fish oil, olive oil can be mixed to obtain a functional oil containing fucosterol. have.

The fucosterol oil, purified fish oil, and olive oil solubilized with the fucosterol may be mixed in a volume ratio of 1 to 5: 5 to 10:80 to 85 to obtain a functional oil containing fucosterol.

The refined fish oil may be used containing 15 to 25% of EPA and DHA. At this time, the refined fish oil is enough to be 15 to 25% by mixing EPA and DHA, so the content of EPA and DHA in refined fish oil can be selected and used.

As an example of the mixing of the fucosterol-solubilized fucosterol oil and fats and oils, the fucosterol-soluble fucosterol oil, evening primrose oil, olive oil can be mixed to obtain a fucosterol-containing functional oil have.

The fucosterol oil, evening primrose oil, and olive oil solubilized with the fucosterol may be mixed in a volume ratio of 1 to 5:50 to 95: 5 to 45 to obtain a functional oil containing fucosterol.

The fucosterol which is an essential component in the functional oil containing the fucosterol of the present invention may be commercially available or may be separated from seaweed.

The algae may be used to extract the water-soluble extract component from the brown algae or brown algae and the remaining hot water extraction residue.

As an example of the brown algae, any one or more selected from kelp, seaweed, green radish, large horsetail, crucian carp, gaedamasima, Ecklonia cava, rhubarb, mabanban, and 톳 may be used.

The fucosterol may be obtained from the algae using the following steps (1) to (5).

(1) extracting the water-soluble extract component from seaweed or seaweed, adding the seaweed raw material of the dried residue of the hot water extraction residue to edible alcohol and then grinding to obtain a seaweed alcohol treatment solution;

(2) adding edible alcohol to the algae liquor treatment solution and then extracting a non-polar substance from the seaweed raw material by extracting reflux with stirring at high temperature by sonication,

(3) filtering the algae liquor treatment solution from which the non-polar substance of the algae material is extracted to obtain a filtrate, and then removing the alcohol to obtain a non-polar extract of the algae raw material,

(4) adding a food additive-grade potassium hydroxide-ethanol solution to the non-polar extract of seaweed raw materials, mixing and hydrolyzing at a high temperature to remove saponified substances, and then cooling to obtain a seaweed hydrolysis solution,

(5) Transfer the seaweed hydrolyzate to the shake-liquid separator for shaking extract, add the non-polar substance and the solvent with different polarity in the seaweed hydrolyzate, extract the mixture, and let it stand to separate the polar fraction and the nonpolar fraction from the liquid-liquid. Removing coexisting water, filtering to remove impurities, and then removing a solvent having a different polarity from that of the nonpolar material, followed by drying to obtain fucosterol.

Separation of the fucosterol from the algae using the steps (1) to (5) above is (a) extracting and separating the non-polar organic component from the algae, and (b) the non-polar organic component separated from the algae From the fucosterol can be obtained by extraction.

Hereinafter, an example of separation of the fucosterol from the seaweed will be described in more detail.

(A) Extraction and Separation of Nonpolar Organic Components from Brown Algae

Extracting the water-soluble extract component from the seaweed or the seaweed and grinding the remaining hot water extraction residue dried to a particle size of 50 to 100 mesh and then extracting the water-soluble extract component from the ground algae or algae and the ground seawater extraction residue dried After extracting the water-soluble extract from the seaweed, add 2-5 times the edible alcohol to the weight of the dried residue, and then use a wet colloid mill or a high-speed mixer of 5,000 rpm or more, preferably 5000-10,000 rpm. A speed blender was used to grind the algae brewing solution at a temperature of 2 to 5 minutes at room temperature, preferably 20 to 25 ° C.

The seaweed may be any one or more brown algae selected from kelp, seaweed, green seaweed, large horsetail, crucian carp, Gaedamashima, Ecklonia cava, rhubarb, maban, 톳.

The algae brewing liquor treated with grinding is transferred to an extraction tank having a stirring function, a heating function, and an ultrasonic wave generating function, and then 3-10 times more edible alcohol is added to the algae brewing solution weight, and then room temperature to 60 ° C, preferably 20 At a temperature of ˜60 ° C., 20 to 50 kHz ultrasonic waves are emitted at a rate of 10 to 20 minutes / hour, and reflux stirring is performed for 1 to 3 hours 1 to 3 times to extract the nonpolar substance contained in the seaweed as much as possible.

The extract obtained by extracting the non-polar substance is filtered by a filter cloth or a press filter or the like to obtain a filtrate, and then concentrated under reduced pressure at 50 to 70 ° C. to remove the alcohol to obtain an extract containing the non-polar substance.

In the above, the edible alcohol may be an ethanol concentration of 90% or more, preferably an ethanol concentration of 90 to 99.9%.

(B) Extraction and separation process of fucosterol from nonpolar components of brown algae

To the extract containing the non-polar substance from which alcohol was removed in step (A), add a food additive-grade potassium hydroxide-ethanol solution (KOH concentration: 5 to 20%) to 0.5 to 4 times the weight of the extract containing the non-polar substance and mix. After hydrolysis at 90 to 120 ° C. for 2 to 6 hours to remove coexisting saponified substances, the mixture is cooled to room temperature, preferably 20 to 25 ° C. to obtain an algae hydrolysis solution. Subsequently, the algae hydrolysate was transferred to a shake-liquid separation device, and then a solvent having a polarity different from that of the non-polar substance contained in the algae hydrolysate was subjected to 1 to 2 times the volume of the algae hydrolysate. The mixture is added to the liquid, shaken and extracted for 1 to 5 minutes at room temperature, preferably at a temperature of 20 to 25 ° C, and then left to separate the liquid and liquid fractions from the polar fractions. Subsequently, anhydrous sodium sulfate (anhydrous) was added to remove the coexisting water, and then filtered by a filter pad or micro filtration to remove the coexisting impurities, and then concentrated under reduced pressure at 30 to 60 ° C. The nonpolar solvent is removed by volatilization in a short time and then dried under a gas stream of nitrogen gas or vacuum dried to obtain fucosterol.

The solvent having a different polarity from the non-polar substance contained in the seaweed hydrolyzate may be water, nucleic acid, or a mixed solvent in which water and nucleic acid are mixed, wherein the mixed solvent is water and nucleic acid 1-9: 9-9. Mixed solvents mixed in a volume ratio of 1 can be used.

The present invention includes a composition for improving blood flow and preventing hyperlipidemia, including the functional oil containing the aforementioned fucosterol.

The present invention includes a composition for treating blood flow improvement and hyperlipidemia including the functional oil containing the above-mentioned fucosterol.

The present invention includes a composition for improving blood flow, preventing and treating hyperlipidemia, including the functional oil containing the aforementioned fucosterol.

The present invention comprises the steps of: (1) extracting and separating nonpolar organic components from seaweeds, and (2) extracting and separating fucosterols from seaweeds, which comprises the steps of extracting and separating fucosterols from the nonpolar organic components separated from the seaweeds. It includes providing a method.

Hereinafter, the content of the present invention will be described in detail through examples and test examples. However, these are intended to explain the present invention in more detail, and the scope of the present invention is not limited thereto.

Example 1 Extraction and Separation Process of Nonpolar Organic Components from Brown Algae

Extract the water-soluble extract from kelp and use the remaining hot water extract residue as a raw material, coarsely crush 5 kg of the raw material into a particle size of 80 mesh, add three times the edible alcohol based on the weight of the raw material, and then use the wet colloid mill three times. Grinding treatment was performed to obtain alcohol treatment kelp powder. Subsequently, the kelp powder drinking liquid is transferred to an extraction tank that can be heated and sonicated. Then, 5 times of edible alcohol is added to the weight of the kelp powder drinking liquid, and 20 kHz ultrasonic wave is fired at a rate of 10 minutes / hour. The mixture was refluxed under stirring for 2 hours and then 1 hour, and the filtrate obtained by filtration with a filter cloth was concentrated under reduced pressure at 70 ° C. to remove alcohol, and then 850 g of a non-polar extract was obtained.

Example 2 Extraction and Separation of Fucosterol from Nonpolar Components of Brown Algae

1 liter of potassium hydroxide-ethanol solution (KOH concentration: 10%) was added to 1.2 kg of the non-polar extract obtained from kelp using the method of Example 1, followed by hydrolysis in a steam bath at 97 ° C. for 5 hours. Transfer the flask to a separating flask, add 2 liters of the mixed solution mixed with water and nucleic acid in a volume of 1: 1, and add it to shake for 1 minute. Then, extract the non-polar component containing the fucosterol from the hydrolysis solution. After standing for 30 minutes, the non-polar extract component is separated into the nucleic acid layer which is a non-polar solvent, and then the nucleic acid layer is fractionated, and anhydrous sodium sulfate (anhydrous) is added to remove the coexisting water, and then filtered with a filter pad and concentrated under reduced pressure at 60 ° C. The resulting nucleic acid was removed, and then dried in vacuo at 40 ° C. to obtain about 4.5 g of crude fucosterol.

Example 3 Fusterol Solubilization and Antioxidation Process

1 g of crude fucosterol and 50 mg of tocopherol acetate obtained in Example 2 were added to 100 ml of olive oil, and then stirred at a temperature of 60 ° C. for 5 minutes to dissolve the solids, and then cooled at room temperature to not differentiate in olive oil, color and flavor. Fucosterol oil was solubilized.

Example 4 Preparation of Functional Enhancement Oil Capsules Blended with Fucosterol and Vegetable Oil

Color and flavor were compared with olive oil by uniformly stirring and mixing 200% of fucosterol oil and 500ml of evening primrose oil and 500 ml of olive oil and 300 ml of olive oil, which were obtained in Example 3, and solubilized. A functionally enhanced mixed oil with more than 53% enhanced in vitro HMG CoA reductase inhibitory activity was obtained without any sensory differences. Subsequently, a fucosterol-containing functional strengthening oil capsule, in which HMG CoA reductase inhibitory activity was enhanced, was prepared by a general manufacturing process of a pharmaceutical soft capsule containing gelatin as a coating material.

<Example 5> Preparation of functional fortified oil mixed with fucosterol and refined fish oil

200 ml of solubilized fucosterol oil containing 0.1% and solubilized fucosterol oil obtained in Example 3, 200 ml of EPA 12% and 3% DHA, 600 ml of olive oil and 3 g of natural tocopherol were uniformly stirred and mixed at 30 ° C. By cooling to obtain a functionally enhanced mixed oil with more than 38% enhanced in vitro HMG CoA reductase inhibitory activity without any sensory differences in color and flavor compared to olive oil.

Experimental Example 1 Extraction Yield of Ethanol Soluble Substance from Hot Water Extract Residue of Kelp

The extraction yields of ethanol-soluble substances according to the extraction conditions were compared with the extracted kelp extract residue from water-soluble extracts as a raw material.The extraction yield of ethanol grinding treatment + ultrasonic heating extraction method was 34.9% higher than that of the simple heating extraction method. (See Table 1).

Table 1. Comparison of Extraction Yields of Ethanol-soluble Compounds of Sea Tangle Powder by Different Extraction Conditions

¹⁾ Extraction condition: Whether to apply pre-extraction or subsidiary extraction under the same extraction solvent, temperature and extraction time

²⁾ Extraction yield: Weight ratio of dry solids of ethanol extract based on the weight of raw material powder

Experimental Example 2 Palatability and Physiological Activity of Fucosterol, Olive Oil, and Omega-3 Fatty Acid-Containing Refined Fish Oil

Sensory Palatability and Cholesterol Synthesis for Coloration and Flavor of the Mixture Composition of 0.1% Fucosterol Oil Based on Olive Oil and Olive Oil and Refined Fish Oil Containing 12% EPA and 3% DHA in Functional Functional Composition Proposed by the Present Invention After a review test for the related enzyme HMG CoA reductase inhibitory activity, fucose 0.1% cholesterol-containing oil and olive oil 200ml 400ml, 400ml purified fish oil and natural tocopherol 3ml sensory preference of a mixed composition eopeumyeonseo the sensual differences as compared to olive oil in In vitro HMG CoA reductase inhibitory activity showed a level of 76.7% enhanced by at least 49% compared to 0.1% fucosterol oil (see Table 2).

Table 2. Inhibitory activity of palatability and cholesterol biosynthesis according to the mixing ratio of fucosterol (A), olive oil (B) and refined fish oil (C)

Mixing ratio (ml) ¹⁾ Palatability ²⁾ HMG-CoA reductase inhibitory activity ³⁾ ( in vitro ,%)  A  B  C D  1,000  - - 3 + 51.3 - 1,000 - 3 ++ 13.6 - - 1,000 3 ± 36.3   200 700 100 3 ++ 43.4   200 600 200 3 ++ 70.8   200 500 300 3 + 73.2   200 400 400 3 ± 76.7

1) A: Oil containing Fucosterol 0.1% based on olive oil, B: Olive oil, C: Refined fish oil (containing 12% EPA, 3% DHA) D: Natural tocopherol

2) Sensory preference (combination of color and flavor):-Extremely poor, ±: Poor, +: Normal, ++: Excellent, +++: Extremely good

3) HMG-CoA reductase inhibitory activity ( in vitro ): cholesterol biosynthesis inhibitory activity

Experimental Example 3 Palatability and Physiological Activity of the Fucosterol and Vegetable Oil-Containing Composition

The organoleptic palatability of color and flavor of the mixed composition containing 200 ml of olive oil-based fucosterol 0.1%, 200 ml of olive oil and 600 ml of evening primrose oil in the functional mixture composition devised by the present invention were compared with olive oil. In Vitro HMG CoA reductase inhibitory activity was enhanced by 58% or more compared to 0.1% fucosterol oil without any sensory difference (see Table 3).

Table 3. Inhibitory activity of palatability and cholesterol biosynthesis according to the mixing ratio of fucosterol (A), olive oil (B) and evening primrose oil (C) (HMG-CoA reductase inhibitory activity)

Mixing ratio (ml) ¹⁾ Palatability ²⁾ HMG-CoA reductase inhibitory activity ³⁾ ( in vitro ,%)  A  B  C  1,000  - - + 51.3 - 1,000 - ++ 13.6 - - 1,000 ++ 34.7   200 400 400 ++ 63.2   200 500 300 ++ 75.1   200 300 500 ++ 78.6   200 200 600 ++ 81.3

1) A: Oil containing Fucosterol 0.1% based on olive oil, B: Olive oil, C: Evening primrose oil

2) Sensory preference (combination of color and flavor):-Extremely poor, ±: Poor, +: Normal, ++: Excellent, +++: Extremely good

3) HMG-CoA reductase inhibitory activity ( in vitro ): cholesterol biosynthesis inhibitory activity

  -HMG-CoA reductase inhibitory activity: pmole number of mevalonate produced by 1 mg microsomal protein for 1 minute

  -HMG-CoA reductase inhibitory activity (%): 100- (sample activity x 100 / control activity), measurement concentration: 50 ㎍ / mL

Experimental Example 4 Antihyperlipidemic Activity of Mixed Composition by Animal Experiment

In order to investigate the antihyperlipidemic activity of the fucosterol-containing mixed composition devised by the present invention in animal experiments, 1% cholesterol, 2% corn oil, Induced hyperlipidemia by incubating for 2 weeks in a high-fat diet mixed with 10% lard, and then divided into 8 groups of experimental animals and divided into 8 dietary groups (Negative control), positive control group (high-fat diet), Fucosterol Control group (FC: high fat diet + olive oil 8ml / kg.bw oral administration), Fucosterol high concentration group (FH: high fat diet + fucosterol 10mg olive oil / kg.bw oral administration), Fucosterol low concentration group (FL: high fat The diet was divided into + fucosterol 1mg and 0.6mg of gamarinorenic acid containing olive oil / kg.bw oral) and bred for 2 weeks, and then collected by blood cholesterol, triglyceride, and low density cholesterol (LDL cholesterol). Terrol), high density cholesterol (HDL cholesterol) and atherosclerosis (AI) were analyzed.

Hyperlipidemia was induced by high-fat diet for 2 weeks, and then high-fat diet and fucosterol mixed milk were administered for 2 weeks, and the results of experimental analysis on serum lipid concentrations of the experimental animals are shown in Table 4.

There was no significant difference in total-cholesterol content according to the experimental diet after hyperlipidemia. However, in the triglyceride (TG) content, which indicates the triglyceride concentration in blood, the experimental group (FL, FH) in the control group of hyperlipidemia induced hyperlipidemia ( 14.6% (FL group) and 12.4% (FH group) were lower than the positive control. In the case of LDL-cholesterol, a hyperlipidemic malignant cholesterol, the fucosterol group showed lower values of 15.0% (FL group) and 10.5% (FH group) than the positive control group. In the HDL-cholesterol content, which inhibits the absorption of cholesterol and has a beneficial physiological effect in improving arteriosclerosis and vascular disorders, the FL and FH groups are 18.7 (FL group) and 30.3% (FH group) compared to the positive control group. ) High level. In addition, the AI index, which is the arteriosclerosis index, was also reduced by about 20% in the FL and FH groups of the low and high concentrations of the fucosterol-administered group, compared to the positive control, so that fucosterol intake significantly reduced the risk of atherosclerosis. It can be seen that. Based on the above results, even if hyperlipidemia was induced by high fat diet, we could expect significant improvement of blood lipid level by ingesting fat containing fucosterol more than 1mg / kg.bw daily. (See FIGS. 1A, 1B, 1C, 1D).

Table 4. Effect of Fucosterol on Blood Lipid Levels in Hyperlipidemia-induced Hamster

Group Total-cholesterol (mg / dL) HDL-cholesterol (mg / dL) LDL-cholesterol (mg / dL) Triglyceride (mg / dL) AI Normal 72.5 ± 11.8 ¹⁾ 25.6 ± 2.9 13.0 ± 2.0 39.4 ± 9.8 2.8 ± 0.6 Control 77.0 ± 14.2 25.7 ± 7.6 15.3 ± 4.0 45.3 ± 9.1 3.0 ± 0.5 FC 78.0 ± 16.1 27.5 ± 3.7 14.5 ± 2.4 57.5 ± 13.6 2.4 ± 0.7 FL 78.7 ± 9.5 33.5 ± 6.9 13.7 ± 3.1 38.7 ± 11.7 2.4 ± 0.4 FH 73.5 ± 13.7 30.5 ± 3.4 13.0 ± 3.6 39.7 ± 12.7 2.4 ± 0.6

Experimental Example 5

In order to investigate the blood flow improvement effect of the fucosterol-containing mixed composition devised by the present invention in the experimental group as in Experiment 4, two weeks after high fat diet induced by hyperlipidemia, After the oral administration of costolol, the blood of experimental animals was taken to examine the effects of fucosterol on the flow of blood.

Improving blood flow in the experimental diet by measuring the time required for capillary passage after injecting blood into artificial capillaries by dividing the blood into 25 μl, 50 μl, 75 μl and 100 μl volumes using the KH-6 Micro channel array flow analyzer. The impact on the system was reviewed. According to the infusion dose of blood, fusterol administration showed better blood flow improvement effect than the positive control group. In particular, the blood flow time of the capillary tube of the experimental group (FL, FH) administered orally with fucosterol up to 50 μl of the blood flow test volume was not significantly different from that of the normal control group (Normal). The improvement effect was shown. At the 75uL level, the blood flow deteriorated to about the same level as the positive control group in the FC group, which was orally administered only vegetable oil with high fat diet. At 100uL level, the blood flow stopped due to capillary obstruction. However, in the FL experimental group administered oral administration of fucosterol-containing fat with high fat diet, 27.7% (75uL) and 14.0% (100uL), respectively, compared to the positive control group, and 40.5% (75uL) and 22.7% in the FH group, respectively. (100 uL) level showed a significant blood flow improvement effect (see Table 5, Figure 2).

Table 5. Effect of fucosterol on blood flow in hamster induced hyperlipidemia

Group 0 uL 25 uL 50 uL 75 uL 100 uL Normal 0 ¹⁾ 8.3 16.7 25.4 33.8 Control 0 18.7 41.7 58.2 64.2 FC 0 12.4 34.5 57.0 ^-2) FL 0 8.6 20.8 42.1 55.2 FH 0 8.8 19.8 34.6 49.6

¹⁾ sec of blood flow, ²⁾ Not applicable

As described above, although described with reference to a preferred embodiment of the present invention, those skilled in the art will be variously modified and modified within the scope of the present invention without departing from the spirit and scope of the present invention described in the claims below. It will be appreciated that it can be changed.

As the results of the above experimental example, the functional oil containing the fucosterol of the present invention, when properly used as an industrial technology, at the same time, the primary function of improving cholesterol metabolism and blood circulation improvement, such as inhibiting cholesterol biosynthesis and lowering blood cholesterol, It can be usefully used as a health functional food material.

In addition, the functional oil containing fucosterol by this firing is an active ingredient with fucosterol which has various and strong functional activity expression characteristics even at low concentrations, and improves cholesterol metabolism and blood purification, anticancer, immune activity enhancement, anti-aging As a raw material of evening primrose seed oil containing gamma linolenic acid (GLA) and refined fish oil containing EPA and DHA, which show various physiological functions such as anti-allergy and anti-allergic, It is possible to easily produce various functional food materials and their application products that can expect the physiological functional activity expression characteristics of raw ingredients such as health foods, and to create and replace high added value by effective utilization of seaweed resources. It is expected to be able to contribute greatly to the establishment of effective utilization technology base as medical material. All.

Claims (6)

A fucosterol-containing functional oil, characterized in that the fucosterol comprises a solubilized fucosterol oil and a fat or oil. The fucosterol oil according to claim 1, wherein the fucosterol oil solubilized is obtained by adding 100 to 500 ml of vegetable oil and 10 to 50 mg of tocophenol to 1 g of fucosterol powder. Contains functional oils. 2. The fucosterol oil solubilized, refined fish oil containing 15-25% of EPA and DHA, olive oil are mixed in a volume ratio of 1-5: 5-10: 80-85. A functional oil containing fucosterol, characterized in that. According to claim 1, wherein the fucosterol solubilized fucosterol oil, evening primrose oil, olive oil is characterized in that the mixture of 1 to 5: 50 to 95: 5 to 45 by volume ratio Functional oil. 3. The functional oil containing fucosterol according to claim 2, wherein the vegetable oil is olive oil. (1) extracting the water-soluble extract component from seaweed or seaweed, adding the remaining seaweed raw material of the dried hot water extraction residue to edible alcohol and then grinding to obtain a seaweed alcohol treatment solution; (2) adding edible alcohol to the algae liquor treatment solution and extracting a non-polar substance from the algae raw material by extracting reflux with stirring at high temperature by ultrasonic treatment; (3) filtering the algae brewing liquor from which the non-polar substance of the algae material is extracted to obtain a filtrate, and then removing the ethanol to obtain a non-polar extract of the algae raw material; (4) adding a food additive-grade potassium hydroxide-ethanol solution to the non-polar extract of seaweed raw materials, mixing and hydrolyzing at high temperature to remove saponified material, and then cooling to obtain a seaweed hydrolyzate, (5) Transfer the algae hydrolysate to the shake-liquid separation device, shake-extract with a nonpolar substance and a solvent with different polarity in the seaweed hydrolyzate, and then settle to separate the liquid and liquid fractions from the polar fraction and the nonpolar fraction. A method for separating fucosterol from seaweed, characterized in that after removing the co-existing water to remove impurities by filtration to remove impurities and then to remove the solvent having a different polarity from the non-polar material and dried to obtain the fucosterol.

Images